Every day, thousands of biopsies are analyzed through processes time-consuming and expensive : successive chemical stains, accumulating delays, and still, weak signals that go unnoticed. Delayed diagnoses, missed nuances – with direct consequences for patients. RainPath is completely reinventing human tissue analysis: thanks to a breakthrough AI, a single image suffices where multiple stains were once necessary. Chemical staining is replaced by virtual staining – faster, more accurate, and frees up pathologists for what truly matters: interpreting, deciding, treating.
The next step
RainPath has ambitious goals for the coming months: to reach 500,000 euros in annual recurring revenue, exceed 100,000 IHC analyses performed, and validate two IHC markers for routine clinical use – while consolidating excellent scientific results on two others. This comprehensive program outlines the emergence of a technology poised to become standard in laboratories.
Why 21st by CentraleSupélec?
21st by CentraleSupélec supports RainPath during this critical phase with clear goals : to exceed €500,000 in annual recurring revenue, to surpass 100,000 IHC analyses performed, to validate two IHC markers for routine clinical use, and to consolidate excellent scientific results on two others. This support is results-oriented, to transform promising scientific advancements into a company that establishes itself as a leader in laboratories.
Focus on the co-founders
Mel Landelle, Antoine Delplace
#AI #DigitalHealth #Biotechnology #DigitalPathology #DeepTech
.avif)
